Replimune Group (NASDAQ:REPL) Stock Price Down 7.1% – Should You Sell?

Shares of Replimune Group, Inc. (NASDAQ:REPL) dropped 7.1% during trading on Wednesday . The company traded as low as $6.68 and last traded at $6.63. Approximately 129,158 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 862,020 shares. The stock had previously closed at $7.14.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on REPL shares. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. BMO Capital Markets lifted their price target on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Finally, HC Wainwright increased their price objective on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Stock Performance

The stock has a market capitalization of $566.06 million, a P/E ratio of -2.39 and a beta of 1.26. The business has a fifty day moving average price of $11.47 and a 200-day moving average price of $11.91. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, sell-side analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its position in shares of Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after buying an additional 52,498 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Replimune Group by 81.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after acquiring an additional 6,748 shares during the last quarter. State Street Corp lifted its stake in Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares in the last quarter. Barclays PLC boosted its holdings in shares of Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after purchasing an additional 98,791 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after purchasing an additional 217,308 shares during the last quarter. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.